The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH/ISH 2016 | Progession of AML treatment over the past decades
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY outlines the limited progress in acute myeloid leukemia (AML) research over the past decades. Standard care is still conventional chemotherapy or lower-intensity therapy generally with a lower dose cytarabine regimens. Practitioners can look at molecular genetics however its application has yet to have a positive influence on the treatment of older AML patients, according to Dr Roboz. Nonetheless, she says there is light on the horizon in the form of improvements to standard care as well as novel agents. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), in Glasgow, Scotland.
